Physician profile
Michael R Macadams
NPI 1477611044
$9,720.00
in general payments reported to CMS, 2019-2025
32 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,083 · 2020: $1,703 · 2021: $1,691 · 2022: $1,710 · 2023: $906 · 2024: $530 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,448.34 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,937.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,395.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $834.08 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Sanofi-Aventis U.S. LLC | $812.86 | 2019-2024 | |
| Amgen INC. | $728.09 | 2019-2025 | Tepezza, Prolia, Evenity |
| Mannkind Corporation | $584.00 | 2019-2025 | |
| Radius Health, INC. | $486.94 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.91 | 2019-2022 | |
| Dexcom, INC. | $388.49 | 2019-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $362.24 | 2019-2022 | |
| Abbvie INC. | $311.70 | 2019-2024 | |
| Corcept Therapeutics | $283.46 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $170.64 | 2021-2025 | |
| Medtronic Minimed, INC. | $140.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $125.15 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $93.47 | 2022-2023 | Tepezza |
| Sequel Med Tech, LLC | $82.48 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $67.95 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $63.65 | 2021-2025 | Minimed 780g |
| Insulet Corporation | $59.90 | 2022-2023 | Omnipod |
| Recordati_rare_diseases_inc. | $47.03 | 2021 | |
| Amarin Pharma, INC. | $41.81 | 2019-2021 | |
| Antares Pharma, INC. | $40.48 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $37.47 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $33.93 | 2023-2025 | Yorvipath |
| Esperion Therapeutics, INC. | $31.43 | 2020-2024 | Nexletol |
| Madrigal Pharmaceuticals | $30.63 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $25.89 | 2019-2021 | |
| Grt US Holding, INC. | $24.84 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.46 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.55 | 2022 | |
| Cequr Corporation | $10.96 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Macadams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.